NCT06486454

Brief Summary

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
67mo left

Started Oct 2024

Longer than P75 for all trials

Geographic Reach
1 country

29 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Oct 2024Nov 2031

First Submitted

Initial submission to the registry

June 27, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 3, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

October 14, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2031

Last Updated

May 6, 2026

Status Verified

April 1, 2026

Enrollment Period

2 years

First QC Date

June 27, 2024

Last Update Submit

April 30, 2026

Conditions

Keywords

histotripsy

Outcome Measures

Primary Outcomes (1)

  • Histotripsy Technical Success

    Histotripsy technical success, defined as completion of histotripsy on the target tumor(s) according to the histotripsy treatment plan, assessed by the treating physician on CT or MR imaging at ≤36 hours post-histotripsy treatment procedure. The histotripsy treatment plan will include identification of the intended complete or partial treatment of the tumor(s). The histotripsy treatment zone must provide target tumor coverage greater than or equal to the degree of treatment intended.

    ≤36 hours post-histotripsy treatment procedure

Study Arms (1)

HistoSonics Edison System

Device: HistoSonics Edison System

Interventions

Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors

Also known as: Histotripsy
HistoSonics Edison System

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects who are 22 years of age or older with a diagnosis of: primary (e.g., HCC, cholangiocarcinoma, angiosarcoma) or metastatic (from other primary cancers) liver cancer, or benign liver tumors (e.g., adenoma).

You may qualify if:

  • Subject is ≥22 years of age
  • Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Informed Consent Form (ICF) prior to any study related tests/procedures and is willing to comply with study procedures and required follow-up assessments
  • Subject's liver tumor(s) can be partially or completely treated with histotripsy

You may not qualify if:

  • Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period
  • Subject is enrolled in an interventional HistoSonics-sponsored trial
  • Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Providence St. Jude

Fullerton, California, 92835, United States

RECRUITING

Mission Hospital

Mission Viejo, California, 92691, United States

RECRUITING

Hoag

Newport Beach, California, 92663, United States

RECRUITING

Sutter Bay Hospitals

San Francisco, California, 94107, United States

RECRUITING

Providence Saint John's Health Center

Santa Monica, California, 90404, United States

RECRUITING

AdventHealth Altamonte Springs

Altamonte Springs, Florida, 32701, United States

WITHDRAWN

AdventHealth Celebration

Celebration, Florida, 34747, United States

RECRUITING

Lee Health Cancer Institute

Fort Myers, Florida, 33905, United States

RECRUITING

Baptist Health Miami Cardiac & Vascular Institute

Miami, Florida, 33176, United States

WITHDRAWN

Northeast Georgia Medical Center

Gainesville, Georgia, 30501, United States

RECRUITING

RUSH University Medical Center

Chicago, Illinois, 60612, United States

RECRUITING

University of Chicago

Chicago, Illinois, 60637, United States

RECRUITING

Willis Knighton Health

Shreveport, Louisiana, 71103, United States

RECRUITING

Mass General Brigham

Boston, Massachusetts, 02115, United States

RECRUITING

Henry Ford Health

Detroit, Michigan, 48202, United States

RECRUITING

University of Michigan Health - West

Wyoming, Michigan, 49519, United States

RECRUITING

Renown Regional Medical Center

Reno, Nevada, 89502, United States

RECRUITING

NYU Langone Health

New York, New York, 10016, United States

RECRUITING

Columbia University Irving Medical Center

New York, New York, 10032, United States

RECRUITING

Weill Cornell Medicine

New York, New York, 10065, United States

RECRUITING

University of Rochester Medical Center

Rochester, New York, 14642, United States

RECRUITING

Miami Valley Hospital South

Centerville, Ohio, 45459, United States

RECRUITING

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

RECRUITING

The Ohio State University

Columbus, Ohio, 43210, United States

RECRUITING

Lehigh Valley Hospital

Allentown, Pennsylvania, 18103, United States

RECRUITING

St. David's Medical Center

Austin, Texas, 78705, United States

RECRUITING

Henrico Doctors' Hospital

Richmond, Virginia, 23229, United States

RECRUITING

Swedish Medical Center

Seattle, Washington, 98122, United States

RECRUITING

University of Wisconsin

Madison, Wisconsin, 53792, United States

RECRUITING

MeSH Terms

Conditions

Liver NeoplasmsCarcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2024

First Posted

July 3, 2024

Study Start

October 14, 2024

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2031

Last Updated

May 6, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations